Brand Reference: Accutane, Absorica, Claravis
| Metric | Verified Benchmark | Source |
|---|---|---|
| Isotretinoin (13-Cis-Retinoic Acid) RxNorm Concept ID | 6064 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.8500 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $345.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | Requires Local / Compounded Rx | Direct Telehealth Formulary |
| Community Mean Out-of-Pocket Paid | $135.00 / mo | 37 Zero-PHI Verified Patient Logs |
Oral 13-cis-retinoic acid isomerized intracellularly to ATRA and 4-oxo-isotretinoin, inducing FOXO1/TRAIL-mediated sebocyte apoptosis to shrink sebaceous gland volume by up to 90%—producing permanent remission in recalcitrant nodulocystic scarring acne.
Classified under Systemic Sebocyte Apoptosis & Pilosebaceous Remodeling Retinoid (Rx), Isotretinoin (13-Cis-Retinoic Acid) exhibits a $210.00/month gap between standard U.S. retail cash counters ($345.00) and verified direct-to-patient routing ($135.00) anchored to $2.8500 CMS unit cost.
Pharmacokinetic profiling of Isotretinoin (13-Cis-Retinoic Acid) demonstrates an elimination half-life of 21 hours parent / 25–29 hours 4-oxo-isotretinoin with 2x higher with high-fat 50g lipid meal (lidose Absorica meal-independent) systemic bioavailability; clearance proceeds via hepatic cyp2c8, cyp2c9, cyp3a4 oxidation to 4-oxo-isotretinoin, reaching clinical onset within 4–8 weeks purge; 120–150 mg/kg cumulative target.
Titration schedules for Isotretinoin (13-Cis-Retinoic Acid) (20 mg PO daily (low-dose micro-regimen) → 0.5 mg/kg/day month 1 -> 1.0 mg/kg/day divided BID with fatty meal) require excluding pregnancy or nursing; concurrent tetracyclines (intracranial hypertension); vitamin a hypervitaminosis supplements; fasting triglycerides > 500 mg/dl; real-world patient logs highlight mucocutaneous cheilitis (95%) (88% of reports), xerosis & dry eyes (52% of reports), triglyceride rise (19% of reports) alongside a 94.50% Worth-It consensus.
Across 37 verified cash-pay logs, Isotretinoin (13-Cis-Retinoic Acid) achieves a 94.50% Worth-It rating with out-of-pocket spend averaging $135.00/mo versus $345.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Local Pharmacy at 20 mg PO daily (low-dose micro-regimen) for Isotretinoin (13-Cis-Retinoic Acid); monthly out-of-pocket dropped to $118.80 compared with $345.00 retail.
Completed 10 weeks on Isotretinoin (13-Cis-Retinoic Acid) (0.5 mg/kg/day month 1 -> 1.0 mg/kg/day divided BID with fatty meal). Zero notable side effects on steady dosing.
Consistent biomarker response on 20 mg PO daily (low-dose micro-regimen) Isotretinoin (13-Cis-Retinoic Acid) sourced via Compounding ($156.60/mo cash pay without insurance prior authorization).